CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients

被引：0
|
作者：
M. V. Lima
G. S. Ribeiro
E. T. Mesquita
P. R. Victer
R. Vianna-Jorge
机构：
[1] Hospital Universitário Antônio Pedro,Departamento de Medicina Clínica
[2] Universidade Federal Fluminense,Departamento de Patologia
[3] Hospital Universitário Antônio Pedro,Departamento de Farmacologia Básica e Clínica
[4] Universidade Federal Fluminense,Coordenação de Pesquisa
[5] Universidade Federal do Rio de Janeiro,undefined
[6] Cidade Universitária,undefined
[7] Centro de Ciências da Saúde,undefined
[8] Instituto Nacional de Câncer,undefined
来源：
European Journal of Clinical Pharmacology | 2008年 / 64卷
关键词：
Gene polymorphism; Brazilians; Warfarin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：9 / 15
页数：6
相关论文
共 50 条
  • [21] CYP2C9 Polymorphism and Unstable Anticoagulation with Warfarin in Patients Within the First 3 Months Following Heart Valve Replacement
    Wypasek, Ewa
    Ciesla, Marek
    Suder, Bogdan
    Janik, Lukasz
    Sadowski, Jerzy
    Undas, Anetta
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 24 (04): : 607 - 614
  • [22] CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese
    Chern, HD
    Ueng, TH
    Fu, YP
    Cheng, CW
    CLINICA CHIMICA ACTA, 2006, 367 (1-2) : 108 - 113
  • [23] Optimisation of warfarin-dosing algorithms for Han Chinese patients with CYP2C9*13 variants
    Wang, Dongxu
    Wu, Hualan
    Zhang, Qing
    Zhou, Xiaoyue
    An, Yang
    Zhao, Anxu
    Chong, Jia
    Wang, Shuanghu
    Wang, Fang
    Yang, Jiefu
    Dai, Dapeng
    Chen, Hao
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 79 (10) : 1315 - 1320
  • [24] Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients
    Huang, Sheng-Wen
    Chen, Hai-Sheng
    Wang, Xian-Qun
    Huang, Ling
    Xu, Ding-Li
    Hu, Xiao-Jia
    Huang, Zhi-Hui
    He, Yong
    Chen, Kai-Ming
    Xiang, Dao-Kang
    Zou, Xiao-Ming
    Li, Qinag
    Ma, Li-Qin
    Wang, Hao-Fei
    Chen, Bao-Lin
    Li, Liang
    Jia, Yan-Kai
    Xu, Xiang-Min
    PHARMACOGENETICS AND GENOMICS, 2009, 19 (03) : 226 - 234
  • [25] Optimisation of warfarin-dosing algorithms for Han Chinese patients with CYP2C9*13 variants
    Dongxu Wang
    Hualan Wu
    Qing Zhang
    Xiaoyue Zhou
    Yang An
    Anxu Zhao
    Jia Chong
    Shuanghu Wang
    Fang Wang
    Jiefu Yang
    Dapeng Dai
    Hao Chen
    European Journal of Clinical Pharmacology, 2023, 79 : 1315 - 1320
  • [26] Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance
    Shaul, Chanan
    Blotnick, Simcha
    Adar, Liat
    Muszkat, Mordechai
    Bialer, Meir
    Caraco, Yoseph
    CLINICAL PHARMACOKINETICS, 2022, 61 (08) : 1187 - 1198
  • [27] Enzymatic activity of 38 CYP2C9 genotypes on ibuprofen
    Yuan, Ling-jing
    Li, Xiang-yu
    Ye, Feng
    Li, Xin-yue
    Li, Qing-qing
    Zhong, Yun-shan
    Wang, Shi-yu
    Wang, Ya-hui
    Hu, Guo-xin
    Cai, Jian-ping
    Li, Jun-wei
    FOOD AND CHEMICAL TOXICOLOGY, 2023, 178
  • [28] Distribution of polymorphisms in the CYP2C9 gene and CYP2C19/CYP2C9 haplotypes among Venezuelan populations
    Flores-Gutierrez, Sara
    Rodriguez-Larralde, Alvaro
    Vivenes de Lugo, Merlyn
    Castro de Guerra, Dinorah
    ANNALS OF HUMAN BIOLOGY, 2017, 44 (02) : 191 - 198
  • [29] Cytochrome P4502C9 (CYP2C9) gene polymorphism and safety off therapy with warfarin
    Mikheeva, Yu. A.
    Kropacheva, E. S.
    Ignatiev, I. V.
    Bulytova, Yu. M.
    Ramenskaya, G. V.
    Sytchev, D. A.
    Dobrovolsky, A. B.
    Panchenko, E. P.
    KARDIOLOGIYA, 2008, 48 (03) : 52 - 57
  • [30] A case of intolerance to warfarin dosing in an intermediate metabolizer of CYP2C9
    Lee, SY
    Kim, JS
    Kim, JW
    YONSEI MEDICAL JOURNAL, 2005, 46 (06) : 843 - 846
12345